Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

The MBTA is suspending Red Line service between Alewife and Park Street for 10 days this month, July 21-30. Here's a look at ...

Acaba la temporada y una de las voces de RAC 1 anuncia por sorpresa que se marcha después de siete años ...

First, let's take a look at Vertex's portfolio and general situation prior to the Crinetics move. As mentioned, the biotech is the global CF leader, specializing in CFTR modulators. These therapies ...

Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire Crinetics Pharmaceuticals. And while the transaction brings Vertex a newly approved potential blockbuster in Palsonify, ...

Vertex Pharmaceuticals VRTX-1.06%decrease; down pointing triangle has agreed to purchase Crinetics Pharmaceuticals CRNX 0.11%increase; up pointing triangle for $10 billion, adding a biopharmaceutical ...

Vertex offers $85 per Crinetics share, a 102% premium to stock's Monday close Deal gives access to Palsonify, an FDA-approved oral pill for adult acromegaly Vertex expects deal to become accretive to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

It has been over four months since I last covered Vertex Pharmaceuticals (VRTX), where I discussed how the company was still the unquestionable leader in cystic fibrosis (CF) but was working to ...

Aguirre y Cia, S.A. y las marcas Motorola, Vertex y E-Tech han llegado a un acuerdo por el cual Aguirre y Cia se convierte en distribuidor en exclusiva para el sector cinegético de los walkies talkies ...

Vertex's chief executive, Reshma Kewalramani. Vertex Pharma's bid to expand beyond its cystic fibrosis franchise has taken a big step forward, thanks to positive late-stage clinical data for ...

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...